Insmed Incorporated · NASDAQ:INSM
Insmed — J.P. Morgan Healthcare Conference January 2024
17 slides from Insmed's conference presentation, Jan 5, 2024
Slide 1: J.P. Morgan Healthcare Conference January 2024
J.P. Morgan Healthcare Conference January 2024
Slide 2: Forward Looking Statement
Forward Looking Statement Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not hist
Slide 3: 2024: The Year of Insmed's Transformation
Brensocatib ASPEN Readout in Bronchiectasis First Phase 2 TPIP Readout in PH-ILD Advance ARIKAYCE® Toward Label Expansion Continued Progress on Cutting-Edge Early Pipeline The Stage is Set for a Breakout Year Rarely Seen in Biotech 2024: The Year of Insmed’s Transformation
Slide 4: Three Programs with Peak Sales Potential > $1 Billion Each
Three Programs with Peak Sales Potential > $1 Billion Each 1 2 3 4 ARIKAYCE Brensocatib TPIP* Early-Stage Research <20% OF EXPENDITURES >80% OF EXPENDITURES *TPIP: Treprostinil Palmitil Inhalation Powder. Peak revenue projection assumes that future unblinded datasets continue to support TPIP’s poten
Slide 5: ARIKAYCE Expected to Continue to Deliver Strong Double-Digit Revenue Growth Globally in 2024
ARIKAYCE Expected to Continue to Deliver Strong Double-Digit Revenue Growth Globally in 2024 ARIKAYCE Full-Year 2024 Revenue Guidance ($340M - $360M) * Slower Growth Period During COVID-19 Pandemic Growth Reacceleration 2024 Guidance Represents ~15% YoY Growth at the Midpoint ($20-$30M sales growth/
Slide 6: ARIKAYCE Expected to Be a >$1 Billion Peak Sales Product Assuming Label Expansion
ARIKAYCE Expected to be a >$1 Billion Peak Sales Product Assuming Label Expansion to Include All Patients with MAC Lung Disease Newly diagnosed NTM MAC could expand the ARIKAYCE commercial opportunity by 3-5 times ARIKAYCE Refractory MAC Lung Patients ~1,400* EU** *Source: Internal analysis of publi
Slide 7: Brensocatib: ASPEN on Track to Read Out in 2Q24
Brensocatib: ASPEN on Track to Read Out in 2Q24 Need One Dose to Win for Regulatory and Commercial Success Clear Win 5th and Final DSMC4 Meeting Held in November 2023 ONE DOSE (either 10mg or 25mg) achieves a p-value1 < 0.01 Anticipated commercial launch timing: Mid-20252 Brensocatib Can File3 ONE
Slide 8: If ASPEN Succeeds, Brensocatib Expected to Become a $5+ Billion Peak Sales Product
If ASPEN Succeeds, Brensocatib Expected to Become a $5+ Billion Peak Sales Product Brensocatib Timeline for Next Steps BiRCh P2 Trial Readout (CRSsNP) ASPEN P3 Trial Readout (Bronchiectasis) P2 Trial Initiation (HS) Launch (Bronchiectasis) 1Assumes indication for non-cystic fibrosis bronchiectasis a
Slide 9: TPIP: Multiple Clinical Readouts Expected in 2024 and 2025
TPIP TPIP: Multiple Clinical Readouts Expected in 2024 and 2025 PAH 45 patients enrolled in Phase 2 study (YE 2023) ~47% average PVR reduction among responders* Phase 2 topline data in 2025 Doubling dose ceiling to 1,280μg from 640μg PH-ILD Phase 2 study fully enrolled (Nov. 2023) Topline readout ex
Slide 10: TPIP: Upcoming Phase 2 Data in PH-ILD Primarily Meant to Characterize Safety Profile
TPIP: Upcoming Phase 2 Data in PH-ILD Primarily Meant to Characterize Safety Profile Favorable tolerability profile in patients with PH-ILD Highest dose (640μg) achieved in majority of patients Treatment-emergent adverse events consistent with underlying disease Pharmacokinetic exploratory endpoi
Slide 11: TPIP Has the Potential to be the Prostanoid of Choice in PH-ILD and PAH Markets
TPIP Has the Potential to be the Prostanoid of Choice in the Multi-Billion Dollar PH-ILD and PAH Markets TPIP TPIP Remodulin® Tyvaso® Yutrepia® Orenitram® Uptravi® Route of administration Inhaled (dry powder) IV orSubcutaneous Inhaled (nebulized and dry powder) Inhaled (dry powder) Oral Oral Dosing
Slide 12: Early-Stage Research: An Assembly of Complementary Platform Technologies
LOW UPFRONT COSTS to acquire the technologies HIGH POTENTIAL IMPACT >30 pre-clinical programs LOW ONGOING EXPENSE <20% of expenditures Early-Stage Research: An Assembly of Complementary Platform Technologies to Answer the Question: “What’s Next?” MULTIPLE CUTTING-EDGE TECHNOLOGIES UNDERPIN INSMED’S
Slide 13: Key Catalysts Set to Transform Insmed in 2024
Key Catalysts Set to Transform Insmed in 2024** Gain regulatory feedback and finalize statistical plan for ENCORE ENCORE Phase 3 full enrollment 13 *Treprostinil Palmitil Inhalation Powder. **Timing for all catalysts are estimated and subject to change. 1 2 3 4 ARIKAYCE Brensocatib TPIP* Early-Stage
Slide 14: …with Many More Important Catalysts Expected in 2025
…with Many More Important Catalysts Expected in 2025** 14 *Treprostinil Palmitil Inhalation Powder. **Timing for all catalysts are estimated and subject to change. ENCORE Phase 3 study topline readout 1 2 3 4 ARIKAYCE Brensocatib TPIP* Early-Stage Research <20% OF EXPENDITURES >80% OF EXPENDITURES B
Slide 15: Shareholder Value Will Be Key Consideration
Shareholder Value Will Be Key Consideration Current Cash Position Offers Insmed Flexibility on the Timing and Form of Any Future Capital Raise Rich event pipeline in next two years Financing options available under all scenarios Convert or Issue Debt Sell Royalty Equity Raise Monetize TPIP Many Fina
Slide 16: Our Purpose and Values Define our Culture at Insmed
Our Purpose and Values Define our Culture at Insmed Where Employees Are Empowered to do their Best Work on Behalf of Patients in Need “I am proud to work at Insmed.” “I am inspired by the work we do.” “I understand how my job helps Insmed achieve success.” “I believe Insmed will be successful in the
Slide 17: Thank You
hank You de
Insmed — J.P. Morgan Healthcare Conference January 2024 on 6ix